Immunological and virological benefits resulted from short-course treatment during primary HIV infection: A meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Chen, Jingjing ^a   Han, Xiaoxu ^a   An, Minghui ^a   Liu, Jing ^a   Xu, Junjie ^a   Geng, Wenqing ^a   Ji, Yangtao ^a   Shang, Hong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; DECISION MAKING; DRUG EFFICACY; DRUG RESISTANCE; DRUG TOXICITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL BENEFIT; META ANALYSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; THERAPY EFFECT; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIROLOGICAL BENEFIT; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84891955269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082461     Document Type: Article

References (38)

1. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11-23. doi:10.1038/nri2674. PubMed: 20010788.
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available: http://www.aidsinfo.nih.gov/contentfiles/ lvguidelines/adultandadolescentgl.pdf. Accessed 2013 Feb 12
3. European Guidelines for treatment of HIV infected adults in Europe. Available: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EACSGuidelines-v6.0-English.pdf. Accessed 2011 Oct
4. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Available: http:// whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf. Accessed 2010
5. Steingrover R, Garcia EF, van Valkengoed IGM, Bekker V, Bezemer D et al. (2010) Transient Lowering of the Viral Set Point After Temporary Antiretroviral Therapy of Primary HIV Type 1. Infection - AIDS Research and Human Retroviruses 26: 379-387. doi:10.1089/aid. 2009.0041.
6. Seng R, Goujard C, Desquilbet L, Sinet M, Rouzioux C et al. (2008) Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 49: 251-258. doi:10.1097/QAI.0b013e318189a739. PubMed: 18845951.
7. Fidler S, Fox J, Touloumi G, Pantazis N, Porter K et al. (2007) Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS 21: 1283-1291. doi:10.1097/QAD.0b013e3280b07b5b. PubMed: 17545704. (Pubitemid 46883482)
8. von Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H et al. (2011) Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLOS ONE 6.
9. Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K et al. (2009) Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 14: 277-283. PubMed: 19661009.
10. Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC et al. (2008) The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 22: 2441-2450. doi:10.1097/QAD. 0b013e328319ea4e. PubMed: 19005267.
11. Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B et al. (1995) A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333: 408-413. doi: 10.1056/NEJM199508173330702. PubMed: 7616989.
12. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C et al. (2012) The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 205: 87-96. doi:10.1093/infdis/jir699. PubMed: 22180621.
13. Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A et al. (2012) No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial. PLoS Med 9: e1001196. PubMed: 22479156.
14. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C et al. (2004) Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 18: 2361-2369. PubMed: 15622312. (Pubitemid 40065903)
15. Fidler S, Porter K, Ewings F, Frater J, Ramjee G et al. (2013) Shortcourse antiretroviral therapy in primary HIV infection. N Engl J Med 368: 207-217. doi:10.1056/NEJMoa1110039. PubMed: 23323897.
16. Mingrone H, Acuipil C, Cordova E, Loiza E, Porteiro N (2010) Temporary antiretroviral therapy during primary HIV-1 infection in Argentina. XVIII. International AIDS Conference [Abstract No. CDB0152].
17. Prazuck T, Hocqueloux L, Rouzioux C, Avettand-Fenoel V, Watier H et al. (2006) Could early and prolonged antiretroviral therapy achieve long-term «remission» in some acutely HIV-1-infected individuals? XVI. International AIDS Conference [Abstract No. CDB0025].
18. Steingrover R, Garcia EF, van Valkengoed IG, Bekker V, Bezemer D et al. (2010) Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses 26: 379-387. doi:10.1089/aid.2009.0041. PubMed: 20377419.
19. Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S et al. (2007) Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 12: 189-193. PubMed: 17503661. (Pubitemid 46569904)
20. Hecht FM, Wang L, Collier A, Little S, Markowitz M et al. (2006) A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 194: 725-733. doi:10.1086/506616. PubMed: 16941337. (Pubitemid 44344118)
21. Streeck H, Jessen H, Alter G, Teigen N, Waring MT et al. (2006) Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 194: 734-739. doi:10.1086/503811. PubMed: 16941338. (Pubitemid 44344119)
22. Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU et al. (2005) Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS 19: 1145-1154. doi:10.1097/01.aids.0000176214.17990.94. PubMed: 15990567. (Pubitemid 41059256)
23. Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP et al. (2007) Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis 195: 546-550. doi:10.1086/510909. PubMed: 17230414. (Pubitemid 46214397)
24. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J et al. (2003) Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77: 11708-11717. doi:10.1128/JVI.77.21.11708-11717.2003. PubMed: 14557656. (Pubitemid 37271669)
25. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M et al. (2005) Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097. doi:10.1038/nature03501. PubMed: 15793563. (Pubitemid 40663481)
26. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD et al. (2000) Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A 97: 3382-3387. PubMed: 10737796. (Pubitemid 30183311)
27. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM et al. (2000) Immune control of HIV-1 after early treatment of acute infection. Nature 407: 523-526. doi:10.1038/35035103. PubMed: 11029005.
28. Chamberland A, Sylla M, Boulassel MR, Baril JG, Côté P et al. (2011) Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection. International Journal STD and Aids 22: 146-150. doi:10.1258/ijsa.2010.010292. PubMed: 21464451.
29. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557. doi:10.1073/pnas.0802203105. PubMed: 18490657. (Pubitemid 351830056)
30. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191: 1410-1418. doi:10.1086/428777. PubMed: 15809898. (Pubitemid 40563351)
31. Chun TW, Moir S, Kovacs C, Fauci AS (2011) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication Reply. AIDS 25: 872-873. doi:10.1097/QAD.0b013e328344c25a.
32. Lifson AR, Krantz EM, Eberly LE, Dolan MJ, Marconi VC et al. (2011) Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Res Ther 8: 2. doi: 10.1186/1742-6405-8-2. PubMed: 21244701.
33. Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M et al. (2011) Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 16: 535-545. doi:10.3851/IMP1776. PubMed: 21685541.
34. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C et al. (2009) Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 23: 1987-1995. doi:10.1097/QAD.0b013e32832eb285. PubMed: 19696651.
35. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954. doi: 10.7326/0003-4819-126-12-199706150- 00003. PubMed: 9182471. (Pubitemid 27255797)
36. Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, Margolick JB (2006) High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy 26: 674-681. doi:10.1592/phco. 26.5.674. PubMed: 16637796. (Pubitemid 43673049)
37. Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Wartel A et al. (2004) Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. HIV Med 5: 326-333. doi:10.1111/j. 1468-1293.2004.00231.x. PubMed: 15369507. (Pubitemid 39276330)
38. Gallant JE, Mehta SH, Sugarman J (2013) Universal Antiretroviral Therapy for HIV Infection: Should US Treatment Guidelines Be Applied to Resource-Limited Settings? Clin Infect Dis 57: 884-887. doi: 10.1093/cid/cit382. PubMed: 23759345.